Overview
The latest medtech venture capital news, updated weekly—tracking major funding rounds of $10M or more in 2026.
For biotech deals, visit our Biotech Funding Tracker, updated weekly.
May 2026
Vortex Imaging
Date: May 18, 2026 Series: Financing round Amount: $12M Therapeutic area: 3D body scans Modality: Ultrasound Investors: 10D Ventures, Entrée Capital, Harel T.E.C Partnership, Connecticut Innovations, PhiFund Ventures
Sunnyvale, Calif., and Givatayim, Israel, based Vortex Imaging Raised $12 Million to accelerate FDA clearance and support of continued development, regulatory clearance, and commercialization of its computational ultrasound system. The system is designed to enable high-quality 3D volumetric imaging using pioneering computational image reconstruction technology that utilizes GPUs-on-Cloud.
Butterfly Medical
Date: May 14, 2026 Series: Series C Amount: $21M Therapeutic area: Benign Prostatic Hyperplasia (BPH) Modality: Implantable device Investors: European Innovation Council (EIC), Junson Capital, MedVenture, New Rhein Healthcare Investors
Based in Boston, Mass., and Yokneam, Israel, Butterfly Medical secured $21 Million in upsized Series C funding to advance its minimally Invasive BPH treatment, which is designed to alleviate the common and debilitating symptoms of BPH. The device already secured CE Mark approval for use in Europe, and is a minimally invasive, implantable solution that mechanically retracts the lateral lobes of the prostate to restore urine flow. It is made to restore and maintain natural urinary flow without the need for cutting, burning or removing tissue, while also being fully reversible.
BlueWind Medical
Date: May 14, 2026 Series: Financing worth $47.8 million in a combination of equity and debt Amount: $47.8 Million Funding Round Therapeutic area: Urgency urinary incontinence (UUI) Modality: Implantable, wearable neuromodulation medical device Investors: Not disclosed
Salt Lake City-based BlueWind closed $47.8 million in financing through a combination of equity and debt. The company will use the proceeds for commercialization and scaling of its Revi System, which is an Implantable Tibial Neuromodulation (ITNM) device used to treat UUI. The device delivers targeted stimulation to the posterior tibial nerve through a lightweight, external wearable. Implanted Revi is done in an outpatient setting and requires local anesthesia.
Urologic Health Inc.
Date: May 14, 2026 Series: Seed Amount: $11 Million Therapeutic area: Bladder dysfunction Modality: Non-invasive urodynamics platform Investors: Edge Medical Ventures, SHD Partners, Longevity Venture Partners
Based in Jersey City, N.J., and Or Yehuda, Israel, Urologic Health closed $11 Million seed financing to advance its niu System, a non-invasive bladder function monitoring device that provides data on conditions such as overactive bladder, urinary retention, and incontinence without catheterization. The funding will go toward the company’s clinical validation, FDA 510(k) regulatory pathway, and initial U.S. commercialization efforts.
Rivermark Medical
Date: May 13, 2026 Series: Series D Amount: $20M Therapeutic area: Benign prostatic hyperplasia (BPH) Modality: Endourethral stent system or prostatic stent Investors: Andera Partners
Based in Milwaukee, Wis., Rivermark Medical raised $20M in Series D funding. The company plans to use the funds for its RAPID III clinical study for its FloStent system that treats men with lower urinary tract symptoms due to BPH. The study is analyzing the safety and efficacy of the stent. The company also intends to use the proceeds to commercialize FloStent when it becomes FDA approved.
UroMems
Date: May 13, 2026 Series: Strategic investment Amount: $60M Therapeutic area: Stress urinary incontinence (SUI) Modality: Implantable artificial urinary sphincter Investors: Ajax Health Fund I
Based out of Minneapolis, Minn., and Grenoble, France, UroMems raised a $60 million strategic investment for its large-scale clinical trials of the UroActive implant. The implant is the first smart automated artificial urinary sphincter (AUS) to treat SUI.
April 2026
Axoft
Date: April 29, 2026 Series: Series A Amount: $55M Therapeutic area: Neurological disorders Modality: Implantable brain-computer interface Investors: C.P. Group Innovation, Alumni Ventures, Hillhouse Investment, Gaorong Ventures
Based in Cambridge, Mass., Axoft raised an oversubscribed $55 million Series A, bringing its total funding to more than $60 million. The company will use the capital to expand its clinical trials across the world and move forward U.S. regulatory approval of its implantable Brain-Computer Interfaces. Proceeds will also go toward helping to build a manufacturing practice facility to mass produce its implantable Brain-Computer Interfaces.
Nervonik
Date: April 27, 2026 Series: Series B Amount: $52.5M Therapeutic area: Chronic pain Modality: Peripheral nerve stimulation (PNS) therapy system Investors: Amzak Health, Foothill Ventures, Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, and Shangbay Capital
Los Angeles, Calif., based Nervonik closed an oversubscribed $52.5 million Series B financing. Funds will go toward development and commercialization of its PNS system, which provides real-time physiological feedback to enhance therapy personalization and efficacy. Early data about the system showed successful recording of evoked compound action potentials (ECAPs), which are neurophysiological biomarkers of nerve activation in response to a therapeutic electrical stimulus, and other biomarkers using implantable leads.
Cala Health
Date: April 20, 2026 Amount: $50 million Series: Growth Capital Therapeutic Area: Essential Tremor & Parkinson’s Modality: Wearable bioelectronic neuromodulation Investors: Trinity Capital
Cala Health secured $50 Million in growth capital to support commercial expansion of its FDA-cleared wearable tremor therapy, kIQ System.
Pulnovo Medical
Date: April 19, 2026 Series: Strategic financing Amount: $100M Therapeutic Area: Pulmonary hypertension & heart failure Modality: Pulmonary Artery Denervation (PADN) Investors: Medtronic, EQT, Qiming Venture Partners, OrbiMed, Lilly Asia Ventures, Gaorong Ventures, HSG
Based out of New York, Pulnovo Medical completed an oversubscribed $100 million strategic financing round. The company also entered into a commercial agreement with its lead investor Medtronic for future commercialization opportunities given Medtronic’s extensive global commercialization capabilities.
Sonire Therapeutics
Date: April 15, 2026 Series: Series A Amount: $18M Therapeutic area: Oncology Modality: High-intensity focused ultrasound (HIFU) therapy for pancreatic cancer Investors: Santé Ventures, Fast Track Initiative, SBI Investment, Nomura SPARX Investment
Palo Alto, Calif., -based Sonire Therapeutics completed $18M in Series A financing. The money raised will be use to accelerate clinical development, support U.S. regulatory progress following the company’s 2024 FDA Breakthrough Device Designation for its HIFU therapy system, which enables precise, effective thermal ablation of tumors in an outpatient environment. The proceeds will also be used to advance global commercialization efforts for the company’s treatment.
Endovascular Engineering (E2)
Date: April 7, 2026 Series: Series C Amount: $80M Therapeutic Area: Pulmonary Embolism Modality: Mechanical thrombectomy medical device Investors: Gilde Healthcare, Norwest, Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, M&L Healthcare Investments
Based in Menlo Park, Calif., E2 raised $80M to market its thrombectomy platform. The funds will support commercialization of the company’s Hēlo Thrombectomy Platform for the treatment of pulmonary embolism. The platform is indicated for the non-surgical removal of emboli and thrombi from pulmonary arteries and venous vasculature.
March 2026
Endogenx
Date: March 25, 2026 Amount: $138M Series: Series C Therapeutic Area: Type 2 diabetes Modality: Non-thermal pulsed electric fields Investors: Arboretum Ventures, more
Minneapolis, Minn., based Endogenx secured a $138 million Series C. The proceeds from this financing will go toward completing the company’s ReCET Clinical Study and support its path to FDA approval. The minimally invasive, outpatient endoscopic procedure uses non-thermal pulsed electric fields to treat inflamed tissue and support healthy cell regeneration in the first section of the small intestine.
Science Corp
Date: March 5, 2026 Series: Series C Amount: $230 M Therapeutic Area: Neurological disorders Modality: Implantable brain-computer interface Investors: Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT, and Quiet Capital, pre-existing investors, and more
Alameda, California-based Science Corp closed a $230 million Series C financing. The capital will see the company through the commercialization of its brain-computer interface retinal implant, PRIMA. The funds will also go toward advancing the company’s core pipeline programs into the clinic.
February 2026
Avisi Technologies
Date: Feb 25, 2026 Series: Series A Amount: $10.7M capital raise Therapeutic area: Glaucoma Modality: Ophthalmic drainage implant Investors: MedVenture Partners, Sherpa Healthcare Partners, SNBL-Gemseki, SBI US Gateway Fund, Golden Seeds, and OneOneFive Good Growth Capital, Accanto Partners, Life Sciences Greenhouse Investment, Quaker Capital Investments
Based out of Redwood City, Calif., Avisi Technologies closed $10.7M in new financing. The funds will go toward the company’s clinical trial SAPPHIRE, which received FDA IDE approval in 2025, and is analyzing the safety and efficacy of VisiPlate, which is a glaucoma treatment device engineered to sustainably reduce intraocular pressure by improving outflow of aqueous. The money raised will also be used to further development Avisi’s treatments for the entire spectrum of glaucomatous disease.
January 2026
Merge Labs
Date: January 15, 2026 Amount: $252M Series: Seed Round Therapeutic Area: Merge biological and artificial intelligence Modality: Brain-computer interface (BCI) platform Investors: Bain Capital, OpenAI
San Franciso, Calif., based Merge Labs, which is co-founded by OpenAI CEO Sam Altman, raised $252 million in a seed round. The proceeds will help accelerate the company’s work toward fusion of biological and artificial intelligence.
MedWatch Technologies
Date: January 14, 2026 Amount: $15 million Series: Series A Therapeutic Area: Diabetes Modality: Non-invasive wearable glucose monitor Investors: Stead Impact Ventures
Las Vegas, Nev.., based MedWatch Technologies, secured $15M Series A financing. The company will use the proceeds for the development of a non-invasive biosensor for glucose-related insight and its integrated lifestyle coaching platform.
Inquis Medical
Date: January 12, 2026 Amount: $75 million Series: Series C Therapeutic Area: Venous thromboembolic disease (VTE) Modality: Mechanical aspiration platform Investors: Undisclosed
Based in Menlo Park, Calif., Inquis Medical closed a $75 million Series C financing round. The proceeds will be used to accelerate commercial expansion of the Aventus Thrombectomy System across the country, as well as toward advancing the company’s next-generation product pipeline.
Ventaris Surgical
Date: Jan 9, 2026 Series: Series A Amount: $30M Therapeutic Area: Kidney stones Modality: Next-gen ureteroscopic system for kidney stone removal Investors: Longitude Capital, Vensana Capital, Atypical Ventures, Neotribe
Ventaris Surgical based out of San Carlos, Calif., completed a $30 million Series A financing round. The company is developing an ureteroscopic system designed to help surgeons achieve more complete stone clearance during kidney stone procedures. Proceeds from the funds will go toward clinical development and advancement of regulatory and commercial milestones.
Spiro Medical
Date: Jan 7, 2026 Series: Series A Amount: $67M Therapeutic Area: Pulmonary Modality: Implantable neuromodulation system for asthma Investors: Andera Partners, Omega Funds, Sherpa Healthcare Partners, HSG (Hong Kong), Supernova Invest (Paris), Northern Light Venture Capital, and Hero Inc. Ltd UK
Spiro Medical, based out of Irvine, Calif., closed a $67 million Series A equity financing round. The company plans to use the funds from the financing to develop a purpose-built Pulmonary Neuromodulation System (PNM) for the treatment of Asthma, and to execute on the clinical work required for regulatory approval in the United States.
